NCT02474212 is a Phase 4 clinical trial of Enoxaparin in Venous Thromboembolism, sponsored by Tampere University Hospital.

Who is sponsoring NCT02474212?

NCT02474212 is sponsored by Tampere University Hospital.

What drugs are being tested in NCT02474212?

Interventions in NCT02474212: Enoxaparin.

What condition does NCT02474212 study?

NCT02474212 studies Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis.

Is NCT02474212 still recruiting?

NCT02474212 is currently completed. Last updated 5 May 2023.

Last reviewed 2023-05-05 · How we verify

NCT02474212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial

Completed Phase 4 Last updated 5 May 2023

What this trial tests

Phase 4 trial testing Enoxaparin in Venous Thromboembolism in 85 participants. Completed in 31 March 2023.

Timeline

1 May 2016

Primary endpoint
31 March 2023

31 March 2023

Quick facts

Lead sponsor	Tampere University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	85
Start date	1 May 2016
Primary completion	31 March 2023
Estimated completion	31 March 2023
Sites	1 location across Finland

Drugs / interventions tested

Enoxaparin — full drug profile →

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →
Pulmonary Embolism — all drugs for Pulmonary Embolism →
Thromboprophylaxis — all drugs for Thromboprophylaxis →

Sponsor

Tampere University Hospital

Who can join

Adults 18 to 90, any sex, with Venous Thromboembolism or Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Anti-Xa concentration maximum 0-24h (Cmax0-24h)
Time frame: 0-24h after initiation of enoxaparin
Anti-Xa concentration maximum level calculated from measured values during 0-24h after initiation of enoxaparin.

Sponsor's own description

To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in postoperative CABG patients, drug is administered either as a continuous intravenous infusion (CIV) or subcutaneous bolus (SCB) once per 72h. Plasma anti-Xa values are measured 12-14 times during study period and concentration maximums calculated to enable comparison of anti-Xa values between administration routes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT07015905 — REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults · Phase 3 · recruiting
NCT06818279 — Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis · Phase 2, PHASE3 · not yet recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Tampere University Hospital trials

Trials by the same sponsor.

NCT07315568 — Couples and Microbial Diversity · not yet recruiting
NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02474212 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
Last refreshed: 5 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02474212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing